• Aucun résultat trouvé

Protease inhibition as new therapeutic strategy for GI diseases

N/A
N/A
Protected

Academic year: 2021

Partager "Protease inhibition as new therapeutic strategy for GI diseases"

Copied!
12
0
0

Texte intégral

Loading

Figure

Table 1 Proteases identified in GI tissues and cells, and disease-associated upregulation
Figure 2 Source of proteases in the GI tract.
Figure 4 Mechanism of action of proteases in GI diseases. PAR, protease-activated receptor.

Références

Documents relatifs

Figure 16. Schematic representation of major findings of this thesis. A) The CD40L-CD40 interaction does not rule pro-inflammatory cytokine production by monocyte/macrophages

There are several challenging and life-threatening com- plications associated with intravenous thrombolysis after acute ischemic stroke that may worsen outcome, such as

Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer

because the recruitment of immune cells to the site of infection ble tumor necrosis factor receptors in cerebrospinal fluid of children forms the basis for the development of

member but it has unexplored potential in various settings, which are of relevance in cancer. NOXA is best known as a selective inhibitor of MCL1, itself overexpressed in many

Dans le troisième chapitre, nous nous intéresserons à la navigation endovasculaire augmentée et à la visualisation des structures vasculaires lors de

Historiquement, le AhR a été décrit comme un récepteur de xénobiotiques mais des observations ou expériences récentes menées dans plusieurs laboratoires laissent

‫ﻣﻘﺪﻣﺔ‪..............................................................................................................:‬‬ ‫ﻻﺷﻚ‪ ،‬ﺃﻥ ﺍﳌﻜﺎﻥ ﻳﺘﺒﻮﺃ ﻣﱰﻟﺔ